PURPOSE: Fine-needle aspiration (FNA) has revolutionised the care of patients with thyroid nodules and is the initial investigation of choice. However, as a result of nondiagnostic (Thy1) and nonneoplastic (Thy2) specimens, it remains an imperfect sole solution with a range of sensitivities and a high inadequate ratio. Therefore the British Thyroid Association (BTA) guidelines recommend a second FNA immediately for Thy1 specimens and 3-6 months later for Thy2 specimens. Patients must be followed up to exclude malignancy. In this study we assessed the performance of MIBI scintigraphy for diagnosing thyroid malignancy and the cost-effectiveness of a combined FNA/MIBI investigative strategy for the management of thyroid nodules. METHODS: The diagnostic performance of MIBI scintigraphy was calculated from a retrospective review of local data combined with a meta-analysis of the published literature. Decision tree analysis was used to calculate the cost-effectiveness of a combined FNA/MIBI investigative strategy compared to the BTA guidelines. RESULTS: From 712 patients, the sensitivity, specificity, PPV and NPV of MIBI scintigraphy for the diagnosis of malignancy were 96 %, 46 %, 34 % and 97 %, respectively. MIBI-based strategies were more accurate and associated with lower cost per patient (£1,855/<euro>2,125 vs. £2,445/<euro>2,801) and lower cost per cancer diagnosed (£1,902/<euro>2,179 vs. £2,469/<euro>2,828) with negligible change in life expectancy. CONCLUSION: Due to its high NPV, MIBI scintigraphy can usefully exclude malignancy for Thy1 and Thy2 lesions. Its low specificity means MIBI scintigraphy cannot be recommended as a first-line investigation, but as a second-line investigation MIBI scintigraphy may lead to a lower rate of unnecessary thyroidectomies. Combined FNA/MIBI strategies are potentially cost-effective in the management of solitary or dominant thyroid nodules.
PURPOSE: Fine-needle aspiration (FNA) has revolutionised the care of patients with thyroid nodules and is the initial investigation of choice. However, as a result of nondiagnostic (Thy1) and nonneoplastic (Thy2) specimens, it remains an imperfect sole solution with a range of sensitivities and a high inadequate ratio. Therefore the British Thyroid Association (BTA) guidelines recommend a second FNA immediately for Thy1 specimens and 3-6 months later for Thy2 specimens. Patients must be followed up to exclude malignancy. In this study we assessed the performance of MIBI scintigraphy for diagnosing thyroid malignancy and the cost-effectiveness of a combined FNA/MIBI investigative strategy for the management of thyroid nodules. METHODS: The diagnostic performance of MIBI scintigraphy was calculated from a retrospective review of local data combined with a meta-analysis of the published literature. Decision tree analysis was used to calculate the cost-effectiveness of a combined FNA/MIBI investigative strategy compared to the BTA guidelines. RESULTS: From 712 patients, the sensitivity, specificity, PPV and NPV of MIBI scintigraphy for the diagnosis of malignancy were 96 %, 46 %, 34 % and 97 %, respectively. MIBI-based strategies were more accurate and associated with lower cost per patient (£1,855/<euro>2,125 vs. £2,445/<euro>2,801) and lower cost per cancer diagnosed (£1,902/<euro>2,179 vs. £2,469/<euro>2,828) with negligible change in life expectancy. CONCLUSION: Due to its high NPV, MIBI scintigraphy can usefully exclude malignancy for Thy1 and Thy2 lesions. Its low specificity means MIBI scintigraphy cannot be recommended as a first-line investigation, but as a second-line investigation MIBI scintigraphy may lead to a lower rate of unnecessary thyroidectomies. Combined FNA/MIBI strategies are potentially cost-effective in the management of solitary or dominant thyroid nodules.
Authors: Y Okumura; Y Takeda; S Sato; M Komatsu; T Nakagawa; S Akaki; M Kuroda; I Joja; Y Hiraki Journal: J Nucl Med Date: 1999-12 Impact factor: 10.057
Authors: Jamie C Mitchell; Frederick Grant; Amy R Evenson; J A Parker; Per-Olof Hasselgren; Sareh Parangi Journal: Surgery Date: 2005-12 Impact factor: 3.982
Authors: T P Links; K M van Tol; P L Jager; J Th M Plukker; D A Piers; H M Boezen; R P F Dullaart; E G E de Vries; W J Sluiter Journal: Endocr Relat Cancer Date: 2005-06 Impact factor: 5.678
Authors: Mark G Shrime; David P Goldstein; Raewyn M Seaberg; Anna M Sawka; Lorne Rotstein; Jeremy L Freeman; Patrick J Gullane Journal: Arch Otolaryngol Head Neck Surg Date: 2007-12
Authors: Frederik A Verburg; Florian F Behrendt; Felix M Mottaghy; Alexander Heinzel Journal: Eur J Nucl Med Mol Imaging Date: 2013-10-11 Impact factor: 9.236
Authors: Alexander Heinzel; Dirk Müller; Florian F Behrendt; Luca Giovanella; Felix M Mottaghy; Frederik A Verburg Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-05 Impact factor: 9.236